การทบทวนตัวชี้วัดของระบบยานานาชาติและประเทศไทย

Woranan Witthayapipopsakul; Viroj Tangcharoensathien

Authors

Woranan Witthayapipopsakul International Health Policy Program, Ministry of Public Health
Viroj Tangcharoensathien International Health Policy Program, Ministry of Public Health

Keywords:

drug systems, performance indicators, monitoring & evaluation

Abstract

Monitoring and evaluation (M&E) is one of crucial functions in the national drug policy. Performance indicators ensure that priority actions are successfully implemented and produce desirable outcomes. Performance indicators should have clarity, usefulness, measurability, reliability, and validity as well as gain acceptance by key stakeholders. It is observed that international M&E frameworks and those existed in Thailand applied common concepts and gave priority to similar components of drug systems. In Thailand, the Thai Drug Watch has once developed 7-dimension drug systems indicators, namely governance, self-reliance, safety, equity, drug quality, accessibility and affordability, and rational use, and analyzed the situation in 2009. Nonetheless, they have not been routinely monitored ever since. Hence, definitive and widely agreed indicators are still lacking apart from the Sustainable Development Goal indicator 3.b, which supports the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries and provides access to affordable essential medicines and vaccines for all. SDG 3.b.3 monitors the proportion of health facilities that have a core set of relevant essential medicines available and affordable on a sustainable basis. The indicators developed and prioritized by the World Health Organization have potentials to be adapted to the Thailand drug system contexts. The National Drug Policy group of the Food and Drug Administration has institutional responsibility to develop and monitor the drug system performance; for which information systems play an important supporting role.

References

Wibulpolprasert S, Chokevivat V, Tantivess S, editors. Thai drug system. Nonthaburi: International Health Policy Program, Thailand; 2002. (in Thai)

Thai Drug System 2020 Committee, Health Systems Research Insititute. Thai Drug Systems 2020 [Internet]. Bangkok: Tana-aroon Printing; 2020 [cited 2021 Mar 10]. 688 p. Available from: https://kb.hsri.or.th/dspace/handle/11228/5234. (in Thai)

Sakulbumrungsil R, Kessomboon N, Kanchanapibool I, Manomayitthikan T, Thathong T, Patikorn C, et al. The impact of drug financing system under Thailand Universal Health Coverage (UHC) on the performance of drug system [Internet]. Journal of Health Science. 2020;29(Special issue, January-February 2020):S59–71. [cited 2021 Mar 10] Available from: https://thaidj.org/index.php/JHS/article/view/8413/8055.

Hafner T, Walkowiak H, Lee D, Aboagye-nyame F. Defining pharmaceutical systems strengthening : concepts to enable measurement. Health Policy Plan. 2017;32(December 2016):572–84.

O’Neill K, Viswanathan K, Celades E, Boerma T. Monitoring, evaluation and review of national health policies, strategies and plans. In: Schmets G, Rajan D, Kadandale S, editors. Strategizing national health in the 21st century: a handbook [Internet]. Geneva: World Health Organization; 2016. [cited 2021 Mar 10] Available from: https://www.who.int/healthsystems/publications/nhpsp-handbook-ch9/en/.

World Health Organization. Monitoring and evaluation. In: How to develop and implement a national drug policy. 2nd ed. [Internet]. Geneva: World Health Organization; 2001. p. 18–20. [cited 2021 Mar 10] Available from: https://www.paho.org/en/file/42678/download?token=48ilfBF7.

Miralles M, Gyton AB, Quick JD. Monitoring and evaluation. In: MDS-3: managing access to medicines and health technologies [Internet]. Arlington: Management Sciences for Health; 2012. p. 48.1-48.20. [cited 2021 Mar 10] Available from: https://www.msh.org/sites/msh.org/files/mds3-ch48-monitoring-mar2012.pdf.

World Health Organization. Monitoring the components and predictors of access to medicines [Internet]. Geneva: World Health Organization; 2019. [cited 2021 Mar 10] Available from: https://www.who.int/medicines/areas/policy/monitoring/monitoring-the-components-of-access-to-medicines.pdf?ua=1.

Hafner T, Walkowiak H. Defining and measuring pharmaceutical systems strengthening: report of the SIAPS Partners’ Consultative Meeting. 2014 Sep 11-12. Arlington, VA; 2014.

Wirtz VJ, Hogerzeil H V, Gray AL, Bigdeli M, de Joncheere CP, Ewen MA, et al. Essential medicines for universal health coverage. Lancet (London, England). 2017 Jan;389(10067):403–76.

United Nations Statistics Division. Global indicator framework for the Sustainable Development Goals and targets of the 2030 Agenda for Sustainable Development [Internet]. New York; 2018. [cited 2021 Mar 10] Available from: https://unstats.un.org/sdgs/indicators/Global-Indicator-Framework-after-refinement_Eng.pdf.

World Health Organization and Health Action International. Measuring medicine prices, availability, affordability and price components [Internet]. 2nd ed. Geneva: World Health Organization; 2008. [cited 2021 Mar 10] Available from: https://www.who.int/medicines/areas/access/OMS_Medicine_prices.pdf?ua=1.

Suchonwanich N, Wananukul W. Improving access to antidotes and antivenoms, Thailand. Bull World Health Organ. 2018 Dec;96(12):853–7.

Food and Drug Administration. Spontaneous reports of ADRs 2017 [Internet]. Nonthaburi: Aksorn Graphic and Design; 2018. [cited 2021 Mar 10] Available from: thaihpvc.fda.moph.go.th/thaihvc/Public/News/uploads/hpvc_1_3_4_100797.pdf.

Suchonwanich N, Sangroongruangsri S, Kittiratchakool N, Jitruknatee A, Limpananont K, Prukpakpoom A, et al. Situation of data and pharmaceutical information systems in Thailand [Internet]. Journal of Health Science. 2020;29(February):S112-28. [cited 2021 Mar 10] Available from: https://thaidj.org/index.php/JHS/article/view/8417/8056.

Phianchana C, Amrumpai Y. Drug systems indicators and factors affecting drug system performance: a case study from a provincial hospital [Internet]. Thai Pharm Heal Sci J. 2010;5(2):138–45. [cited 2021 Mar 10] Available from: http://ejournals.swu.ac.th/index.php/pharm/article/view/2599/2612.

Kanjanarat P, Boriharn S, Putthasri W, Silkavute P. Rationale drug use indicators in Thailand [Internet]. Nonthaburi: Health Systems Research Institute, Thai Drug System Development Research Network, International Health Policy Program; 2015. [cited 2021 Mar 10] Available from: https://kb.hsri.or.th/dspace/bitstream/handle/11228/4245/hs2129.pdf?sequence=3&isAllowed=y. (in Thai)

Pharmaceutical System Research & Development Foundation. International drug systems indicators and recommendations for Thailand [Internet]. [cited 2021 Mar 10] Available from: https://www.hiso.or.th/hiso/picture/reportHealth/nn_report9_10.pdf. (in Thai)

Thai Drug Watch. Situation of drug system 2009 [Internet]. Bangkok: Thai Health Promotion Foundation, Thai Drug Watch; 2009. [cited 2021 Mar 10] Available from: http://www.thaidrugwatch.org/download/otherprint/otherprint01.pdf. (in Thai)

World Health Organization. Measuring transparency in medicines registration, selection and procurement: four country assessment studies [Internet]. Geneva: World Health Organization; 2006. [cited 2021 Mar 10] Available from: https://www.who.int/medicines/areas/policy/goodgovernance/Transparency4CountryStudy.pdf.